FibroBiologics
FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. The company holds over 240 patents across various clinical pathways, including multiple sclerosis, cartilage repair, degenerative disc disease, cancer, wound healing, and life extension programs. It aims to revolutionize treatment paradigms for chronic diseases using its proprietary fibroblast platform, which is based on the most common cell in the human body, fibroblasts. The company is led by a team of experienced executives and scientific advisors, and is actively engaged in research, development, and clinical trials to bring innovative therapies to market.
Industries
Nr. of Employees
small (1-50)
FibroBiologics
Products
Pipeline of fibroblast-based therapeutic candidates
A portfolio of clinical-stage and preclinical fibroblast cell-based and fibroblast-derived product candidates targeting chronic diseases and regenerative indications such as multiple sclerosis, degenerative disc disease, wound healing, cancer, and thymic/splenic involution.
CybroCell
Fibroblast-derived cell therapy for degenerative disc disease with FDA IND clearance.
CYWC628
Fibroblast-based cell therapy candidate designed to accelerate wound healing and recruit stem cells for tissue remodeling.
TBC190
Discovery phase project aiming to reverse thymic involution, restore thymus function, and suppress the impact of aging on the immune system.
CYAPO913
Discovery phase project providing an insulin-producing artificial pancreatic organoid with immune resistance for diabetes treatment.
CYMS101
Cell therapy candidate targeting multiple sclerosis by stimulating remyelination and endogenous neural stem cells.
Pipeline of fibroblast-based therapeutic candidates
A portfolio of clinical-stage and preclinical fibroblast cell-based and fibroblast-derived product candidates targeting chronic diseases and regenerative indications such as multiple sclerosis, degenerative disc disease, wound healing, cancer, and thymic/splenic involution.
CybroCell
Fibroblast-derived cell therapy for degenerative disc disease with FDA IND clearance.
CYWC628
Fibroblast-based cell therapy candidate designed to accelerate wound healing and recruit stem cells for tissue remodeling.
TBC190
Discovery phase project aiming to reverse thymic involution, restore thymus function, and suppress the impact of aging on the immune system.
CYAPO913
Discovery phase project providing an insulin-producing artificial pancreatic organoid with immune resistance for diabetes treatment.
CYMS101
Cell therapy candidate targeting multiple sclerosis by stimulating remyelination and endogenous neural stem cells.
Services
Research and development services to discover, characterize and advance fibroblast-based therapeutic candidates toward clinical evaluation.
Development and application of molecular assays (genomic, proteomic, epigenetic) to support product characterization and biomarker identification.
Research and development services to discover, characterize and advance fibroblast-based therapeutic candidates toward clinical evaluation.
Development and application of molecular assays (genomic, proteomic, epigenetic) to support product characterization and biomarker identification.
Expertise Areas
- Fibroblast cell therapy development
- Preclinical and early clinical development
- Cell culture and cell therapy platform engineering
- Biomarker and molecular assay development
Key Technologies
- Fibroblast cell-based therapeutics
- Primary cell culture and differentiation
- Next-generation sequencing workflows
- Proteomics
News & Updates
The company released its annual report for the year ended December 31, 2022, highlighting its progress in developing fibroblast cell-based therapeutics.
The company surpassed $6,900 per investor in its crowdfunding campaign on StartEngine.
The company announced its participation in the Biotech Showcase in San Francisco from January 8-10, 2024.
FibroBiologics Raises Capital and Advances Pipeline
FibroBiologics continues to secure funding and develop its fibroblast therapies for chronic diseases.
Innovative Fibroblast Therapies in Development
The company is pioneering new treatments using fibroblast cell-based therapies.
Company Updates and Future Plans
FibroBiologics shares its strategic plans for growth and clinical development.
The company released its annual report for the year ended December 31, 2022, highlighting its progress in developing fibroblast cell-based therapeutics.
The company surpassed $6,900 per investor in its crowdfunding campaign on StartEngine.
The company announced its participation in the Biotech Showcase in San Francisco from January 8-10, 2024.
FibroBiologics Raises Capital and Advances Pipeline
FibroBiologics continues to secure funding and develop its fibroblast therapies for chronic diseases.
Innovative Fibroblast Therapies in Development
The company is pioneering new treatments using fibroblast cell-based therapies.
Company Updates and Future Plans
FibroBiologics shares its strategic plans for growth and clinical development.